Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;78(2):131-136.
doi: 10.1016/j.ando.2017.04.013. Epub 2017 Apr 27.

X-LAG: How Did They Grow So Tall?

Affiliations
Free article
Review

X-LAG: How Did They Grow So Tall?

Albert Beckers et al. Ann Endocrinol (Paris). .
Free article

Abstract

X-linked acrogigantism (XLAG) is a new, pediatric-onset genetic syndrome, due to Xq26.3 microduplications encompassing the GPR101 gene. XLAG has a remarkably distinct phenotype with disease onset occurring before the age of 5 in all cases described to date, which is significantly younger than in other forms of pituitary gigantism. These patients have mixed GH and prolactin positive adenomas and/or mixed-cell hyperplasia and highly elevated levels of GH/IGF-1 and prolactin. Given their particularly young age of onset, the significant GH hypersecretion can lead to a phenotype of severe gigantism with very advanced age-specific height Z-scores. If not adequately treated in childhood, this condition results in extreme final adult height. XLAG has a clinical course that is highly similar to some of the tallest people with gigantism in history.

Keywords: Familial isolated pituitary adenoma (FIPA); GPR101 gene; Gigantism; Le gigantisme; Le gène GPR101; L’acro-gigantisme lié au chromosome X (X-LAG); L’adénome hypophysaire; L’adénome hypophysaire familial isolé (FIPA); Pituitary adenoma; X-linked acrogigantism (X-LAG).

Similar articles

  • Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.
    Iacovazzo D, Caswell R, Bunce B, Jose S, Yuan B, Hernández-Ramírez LC, Kapur S, Caimari F, Evanson J, Ferraù F, Dang MN, Gabrovska P, Larkin SJ, Ansorge O, Rodd C, Vance ML, Ramírez-Renteria C, Mercado M, Goldstone AP, Buchfelder M, Burren CP, Gurlek A, Dutta P, Choong CS, Cheetham T, Trivellin G, Stratakis CA, Lopes MB, Grossman AB, Trouillas J, Lupski JR, Ellard S, Sampson JR, Roncaroli F, Korbonits M. Iacovazzo D, et al. Acta Neuropathol Commun. 2016 Jun 1;4(1):56. doi: 10.1186/s40478-016-0328-1. Acta Neuropathol Commun. 2016. PMID: 27245663 Free PMC article.
  • Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.
    Rodd C, Millette M, Iacovazzo D, Stiles CE, Barry S, Evanson J, Albrecht S, Caswell R, Bunce B, Jose S, Trouillas J, Roncaroli F, Sampson J, Ellard S, Korbonits M. Rodd C, et al. J Clin Endocrinol Metab. 2016 May;101(5):1927-30. doi: 10.1210/jc.2015-4366. Epub 2016 Mar 16. J Clin Endocrinol Metab. 2016. PMID: 26982009 Free PMC article.
  • Gigantism: X-linked acrogigantism and GPR101 mutations.
    Iacovazzo D, Korbonits M. Iacovazzo D, et al. Growth Horm IGF Res. 2016 Oct-Dec;30-31:64-69. doi: 10.1016/j.ghir.2016.09.007. Epub 2016 Sep 29. Growth Horm IGF Res. 2016. PMID: 27743704 Review.
  • X-Linked Acrogigantism.
    Iacovazzo D, Korbonits M. Iacovazzo D, et al. 2018 Feb 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020. GeneReviews®. 1993–2020. PMID: 29389097 Free Books & Documents. Review.
  • X-linked acrogigantism syndrome: clinical profile and therapeutic responses.
    Beckers A, Lodish MB, Trivellin G, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong CS, Caberg JH, Verrua E, Naves LA, Cheetham TD, Young J, Lysy PA, Petrossians P, Cotterill A, Shah NS, Metzger D, Castermans E, Ambrosio MR, Villa C, Strebkova N, Mazerkina N, Gaillard S, Barra GB, Casulari LA, Neggers SJ, Salvatori R, Jaffrain-Rea ML, Zacharin M, Santamaria BL, Zacharieva S, Lim EM, Mantovani G, Zatelli MC, Collins MT, Bonneville JF, Quezado M, Chittiboina P, Oldfield EH, Bours V, Liu P, W de Herder W, Pellegata N, Lupski JR, Daly AF, Stratakis CA. Beckers A, et al. Endocr Relat Cancer. 2015 Jun;22(3):353-67. doi: 10.1530/ERC-15-0038. Epub 2015 Feb 24. Endocr Relat Cancer. 2015. PMID: 25712922 Free PMC article.
See all similar articles

Cited by 1 article

Feedback